| Gene symbol | LAMP3 | Synonyms | CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3, TSC403 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q27.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | lysosomal associated membrane protein 3 | ||||
| Gene symbol | UL83 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 | dbXrefs | |
| Description | tegument protein pp65 | ||||
| GTO ID | GTC0479 |
| Trial ID | NCT03927222 |
| Disease | Glioblastoma |
| Altered gene | UL83|LAMP |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | CMV-specific dendritic cells Vaccine |
| Co-treatment | Temozolomide|Tetanus-Diphtheria Toxoid (Td)|GM-CSF|111-Indium-labeling of Cells for in vivo Trafficking Studies |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | I-ATTAC: Improved Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma |
| Year | 2019 |
| Country | United States |
| Company sponsor | Mustafa Khasraw, MBChB, MD, FRCP, FRACP |
| Other ID(s) | Pro00090683 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||